Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

40.50USD
17 Nov 2017
Change (% chg)

$0.45 (+1.12%)
Prev Close
$40.05
Open
$39.75
Day's High
$40.65
Day's Low
$39.05
Volume
102,349
Avg. Vol
193,068
52-wk High
$43.90
52-wk Low
$13.35

Chart for

About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The... (more)

Overall

Beta: --
Market Cap(Mil.): $1,412.94
Shares Outstanding(Mil.): 43.68
Dividend: --
Yield (%): --

Financials

BRIEF-Global Blood Therapeutics says DSMB safety review for phase 3 HOPE study completed

* Global Blood Therapeutics announces completion of safety review by independent data and safety monitoring board (DSMB) for phase 3 HOPE study in sickle cell disease Source text for Eikon: Further company coverage:

13 Nov 2017

BRIEF-Global Blood Therapeutics posts Q3 loss per share $0.66

* Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results

03 Nov 2017

BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440

* Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440

24 Oct 2017

BRIEF-Global Blood Therapeutics announces discontinuation of IPF program

* Global Blood Therapeutics announces discontinuation of Idiopathic Pulmonary Fibrosis (IPF) program​

23 Oct 2017

BRIEF-Point72 Asset Management LP reports 5.2 pct passive stake in Global Blood Therapeutics

* Point72 Asset Management LP reports 5.2 percent passive stake in Global Blood Therapeutics Inc ‍​as of October 2 - SEC filing Source text: (http://bit.ly/2yH9e9Y) Further company coverage:

04 Oct 2017

BRIEF-Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease

* Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease (scd) Source text for Eikon: Further company coverage:

05 Sep 2017

BRIEF-Global Blood Therapeutics Q2 loss per share $0.55

* Global Blood Therapeutics reports recent business progress and provides second quarter 2017 financial results

08 Aug 2017

BRIEF-Global Blood Therapeutics expands ongoing Phase 2A hope-kids 1 study into younger pediatric population

* Global Blood Therapeutics expands ongoing phase 2A hope-kids 1 study into younger pediatric population

10 Jul 2017

BRIEF-Global Blood Therapeutics receives EMA PRIME designation for GBT440

* Global blood therapeutics receives ema prime designation for gbt440 for the treatment of sickle cell disease (scd) Source text for Eikon: Further company coverage:

28 Jun 2017

Earnings vs. Estimates